Trove
Sign In Sign Up

New Leaf team

Person
Mentions
6
Relationships
2
Events
1
Documents
3
Search

Relationship Network

Loading... nodes
Interactive Network: Click nodes or edges to highlight connections and view details with action buttons. Drag nodes to reposition. Node size indicates connection count. Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak). Use legend and help buttons in the graph for more guidance.

Event Timeline

Interactive Timeline: Hover over events to see details. Events are arranged chronologically and alternate between top and bottom for better visibility.
2 total relationships
Connected Entity Relationship Type
Strength (mentions)
Documents Actions
organization Sprout
Management historical affiliation
5
1
View
organization Sprout
Financial
5
1
View
Date Event Type Description Location Actions
2005-01-01 N/A Founding of New Leaf Ventures N/A View

HOUSE_OVERSIGHT_024052.jpg

This document appears to be page 41 of a confidential investment memorandum for 'New Leaf,' specifically regarding their third fund, NLV-III. It outlines the 'Medical Devices Investment Strategy,' emphasizing a shift toward later-stage opportunities due to regulatory headwinds in the U.S. and E.U. The document cites specific portfolio successes like Neuronetics, CardioKinetix, and the acquisition of Interlace Medical by Hologix to demonstrate the team's track record.

Investment memorandum / fund strategy report
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024045.jpg

This document is a confidential investment report page (marked House Oversight) detailing the track record of New Leaf Ventures (NLV) in the biopharmaceutical sector. It highlights their investment strategy, networking capabilities, and specific performance metrics (multiples on invested capital) for various portfolio companies across funds NLV-I, NLV-II, and Sprout Funds. The text lists specific exits and IPOs occurring between 2011 and 2013.

Investment report / confidential memorandum (house oversight evidence)
2025-11-19
Analysis Source

HOUSE_OVERSIGHT_024033.jpg

This document is a confidential financial report summarizing the investment performance of New Leaf Ventures and Sprout Funds by sector as of March 31, 2014. It details performance metrics (Gross Value, Multiple, and IRR) for Biopharmaceutical and Information Convergence investments across multiple funds dating back to 1993. The document carries a House Oversight Committee stamp, indicating it was part of a congressional investigation.

Financial performance report / investment summary
2025-11-19
Analysis Source
Total Received
$0.00
0 transactions
Total Paid
$945,000,000.00
1 transactions
Net Flow
-$945,000,000.00
1 total transactions
Date Type From To Amount Description Actions
2014-03-31 Paid New Leaf team Biopharmaceutical... $945,000,000.00 Aggregate investment in 64 biopharmaceutical in... View
As Sender
0
As Recipient
0
Total
0
No communications found for this entity. Entity linking may need to be improved.

Discussion 0

Sign in to join the discussion

No comments yet

Be the first to share your thoughts on this epstein entity

Back to Search